PT1848813E - Activação de glicolípidos bacterianos de células nkt restritas ao cd1d - Google Patents

Activação de glicolípidos bacterianos de células nkt restritas ao cd1d Download PDF

Info

Publication number
PT1848813E
PT1848813E PT67339218T PT06733921T PT1848813E PT 1848813 E PT1848813 E PT 1848813E PT 67339218 T PT67339218 T PT 67339218T PT 06733921 T PT06733921 T PT 06733921T PT 1848813 E PT1848813 E PT 1848813E
Authority
PT
Portugal
Prior art keywords
glycolipid
cells
alkyl
nkt
cell
Prior art date
Application number
PT67339218T
Other languages
English (en)
Portuguese (pt)
Inventor
Luc Teyton
Albert Bendelac
Paul Savage
Original Assignee
Scripps Research Inst
Univ Chicago
Univ Brigham Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ Chicago, Univ Brigham Young filed Critical Scripps Research Inst
Publication of PT1848813E publication Critical patent/PT1848813E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT67339218T 2005-01-28 2006-01-26 Activação de glicolípidos bacterianos de células nkt restritas ao cd1d PT1848813E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28

Publications (1)

Publication Number Publication Date
PT1848813E true PT1848813E (pt) 2013-07-15

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67339218T PT1848813E (pt) 2005-01-28 2006-01-26 Activação de glicolípidos bacterianos de células nkt restritas ao cd1d

Country Status (12)

Country Link
US (1) US9295722B2 (https=)
EP (1) EP1848813B1 (https=)
JP (1) JP5053101B2 (https=)
AU (1) AU2006211485B2 (https=)
BR (1) BRPI0607299A2 (https=)
CA (1) CA2593715C (https=)
DK (1) DK1848813T3 (https=)
ES (1) ES2423005T3 (https=)
PL (1) PL1848813T3 (https=)
PT (1) PT1848813E (https=)
WO (1) WO2006083671A2 (https=)
ZA (1) ZA200706208B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
PL2056842T3 (pl) 2006-04-07 2013-03-29 Scripps Research Inst Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
JP2010523724A (ja) * 2007-04-13 2010-07-15 アカデミア シニカ α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
US8207135B2 (en) 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
WO2010097700A1 (en) 2009-02-25 2010-09-02 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CA2893918C (en) * 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas
EP4262997A1 (en) * 2020-12-18 2023-10-25 L'oreal Extract of bacteria of the genus sphingomonas
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法
WO2024107463A1 (en) * 2022-11-14 2024-05-23 The Trustees Of Columbia University In The City Of New York 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (https=) 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (en) 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
RO117533B1 (ro) 1993-05-14 2002-04-30 Cytel Corp San Diego DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001515868A (ja) * 1997-09-12 2001-09-25 ブライハム アンド ウイメンズ ホスピタル Ｃｄ１制限免疫応答のための合成抗原
AU2001252599A1 (en) 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
AU2002213588A1 (en) * 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
KR100549866B1 (ko) * 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
JP5005541B2 (ja) 2004-09-03 2012-08-22 ザ ユニヴァーシティー オヴ シカゴ Ｎｋｔ細胞の活性化方法
PL2056842T3 (pl) 2006-04-07 2013-03-29 Scripps Research Inst Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use

Also Published As

Publication number Publication date
EP1848813A4 (en) 2008-07-09
US9295722B2 (en) 2016-03-29
ES2423005T3 (es) 2013-09-17
AU2006211485B2 (en) 2011-04-14
DK1848813T3 (da) 2013-07-15
US20080279894A1 (en) 2008-11-13
EP1848813B1 (en) 2013-04-10
CA2593715C (en) 2015-05-05
WO2006083671A2 (en) 2006-08-10
AU2006211485A1 (en) 2006-08-10
WO2006083671B1 (en) 2007-04-12
CA2593715A1 (en) 2006-08-10
PL1848813T3 (pl) 2013-09-30
EP1848813A2 (en) 2007-10-31
BRPI0607299A2 (pt) 2009-08-25
ZA200706208B (en) 2008-04-30
JP5053101B2 (ja) 2012-10-17
JP2008528608A (ja) 2008-07-31
WO2006083671A3 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
PT1848813E (pt) Activação de glicolípidos bacterianos de células nkt restritas ao cd1d
Chang et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity
Wesch et al. Modulation of γδ T cell responses by TLR ligands
Carreño et al. Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
Duramad et al. Pharmacologic expansion of donor-derived, naturally occurring CD4+ Foxp3+ regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models
Haque et al. Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 mice by activation of NK cells and NK-T cells
Hogan et al. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide
Yuan et al. A Streptococcus pneumoniae endolysin mutant protein ΔA146Ply elicits rapid broad-spectrum mucosal protection in mice via upregulation of GPX4 through TLR4/IRG1/NRF2 to alleviate macrophage ferroptosis
Montalvillo et al. Innate lymphoid cells and natural killer T cells in the gastrointestinal tract immune system
Fujiwara et al. Bacterial sphingophospholipids containing non-hydroxy fatty acid activate murine macrophages via Toll-like receptor 4 and stimulate bacterial clearance
Ongol et al. Potential of selected strains of lactic acid bacteria to induce a Th1 immune profile
Saito et al. Protective and therapeutic efficacy of Lactobacillus casei against experimental murine infections due to Mycobacterium fortuitum complex
US7928088B2 (en) Th1 cell differentiation accelerator
Hart Increased sensitivity of Corynebacterium parvum-treated mice to toxic effects of indomethacin and lipopolysaccharide
Nasrallah et al. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity
Ohtsubo et al. Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2, 3, 6'-trimycolate
McPherson Evaluation of the Mode of Action of Sulfated Lactosyl Archaeol Adjuvant: Interaction with L-selectin and Impact of Administration Route
Alwethaynani Exploiting the potential of iNKT cells to improve vaccination
Mierzejewska et al. De-O-acylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity
Bhattcharya Immunology and Microbiology
Matham et al. Immune Targets Druggability of Mycoplasma synoviae in Chicken
da Costa Leishmania Infantum Extracellular Material and Human Invariant Natural Killer T Cells: A Functional Study.
US20080152626A1 (en) Method for Activating Cd8 T Cells
Alley et al. Effect of inoculation with neuraminidase-treated tumor cells on macrophage cytotoxicity in vitro
Martner Regulation of innate and adaptive immune responses by Gram-positive and Gram-negative bacteria